Gilead Sciences Inc
NASDAQ: GILD
$83.94
+$0.04 (+0.0%)
Closing Price on September 20, 2024
GILD Articles
UBS reports that corporations are generating an incredible $1 trillion a year in cash, and the believe these five top companies will stay focused on returning capital to shareholders.
Published:
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Bought as a basket, these four companies could offer long-term investors a perfect compliment of stocks covering the health care sector.
Published:
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
Published:
The stock market continues to act like an aging prize fighter, one that will not give up despite all the haymakers landed. In keeping with the bullish tone, insiders continue buying stock.
Published:
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Credit Suisse downgraded Gilead Sciences to Neutral and lowered its price target, citing increased competition for hepatitis C drugs.
Published:
Friday's top analyst upgrades, downgrades and initiations include Best Buy, Gilead Sciences, KeyCorp, National Bank of Greece, Pandora Media, Staples and Yelp.
Published:
Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a move follows Amgen.
Published:
Gilead Sciences reported better-than-expected fourth-quarter results Tuesday after the markets closed.
Published:
Last Updated:
Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.
Published:
24/7 Wall St. has put together a preview of some of the larger companies reporting quarterly results in the coming week.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
Published:
Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year to date, Its shares are up 11%.
Published:
Last Updated:
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published: